Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism
- Joel G. Ray, MD, MSc;
- Clive Kearon, MD, PhD;
- Qilong Yi, PhD;
- Patrick Sheridan, MSc;
- Eva Lonn, MD, MSc; and
- for the Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators*
-
From St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, and the Population Health Research Institute,
Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada.
-
Figure 1. *Limited to the 3306 participants for whom homocysteine was measured at baseline. †Homocysteine level >13.8 µmol/L. Risk for venous thromboembolism (VTE) in prespecified subgroups.
-
Figure 2. Cumulative proportion of participants with venous thromboembolism.
Responses to this article
-
Ann Intern Med
June 5, 2007
vol. 146
no. 11
761-767
RSS Feeds
Figure 1. *Limited to the 3306 participants for whom homocysteine was measured at baseline. †Homocysteine level >13.8 µmol/L. Risk for venous thromboembolism (VTE) in prespecified subgroups.
Figure 2. Cumulative proportion of participants with venous thromboembolism.
Related Clinical Content
